Tenaya Therapeutics is a preclinical-stage, Series C, privately-held biopharmaceutical company that is shaping the future of heart disease treatment driven by a bold mission: to discover, develop and deliver curative therapies that address the underlying drivers of disease. Tenaya is developing therapies for rare genetic disorders as well as for more prevalent heart conditions through three platforms: Gene Therapy, Regeneration and Precision Medicine. Founded by leading cardiology researchers at the Gladstone Institutes and UT Southwestern, Tenaya is backed by a top-tier syndicate of investors, including The Column Group, Casdin Capital, RA Capital, RTW, Fidelity, T Rowe Price, GV and others. Tenaya Therapeutics currently has 75+ full-time employees (not including consultants) and is headquartered in South San Francisco, California, USA. For more information, please visit www.TenayaTherapeutics.com and follow us on LinkedIn.